Preeclampsia Clinical Trials 2023

What are the top hospitals conducting preeclampsia research?

Preeclampsia, a potentially dangerous condition that affects pregnant women, is the focus of cutting-edge clinical trials taking place at various top hospitals across the United States. Northwestern University in Chicago has emerged as a leader in preeclampsia research with three active trials and eight completed trials since their inaugural investigation in 2003. In Iowa City, the University of Iowa is making significant contributions to understanding this condition through its current involvement in three active preeclampsia trials and five previous studies since 2018.

Remarkably, Magee Women's Hospital of UPMC in Pittsburgh has also taken up the mantle with two ongoing preeclampsia trials and an additional three completed studies since joining the field just a few years ago. Meanwhile, researchers at the University of Texas Medical Branch located in Galveston are conducting two active preeclampsia trials alongside their impressive track record of six past investigations that began back in 2003.

Lastly adding itself to this list is The Medical College of Wisconsin situated within Wauwatosa; although relatively new on this front they have already begun making strides with one existing trial while being credited for initiating their very first study on preeclampsiain 2022

These institutions represent beacons of hope for pregnant women affected by preeclampsia worldwide as dedicated medical professionals strive towards better understanding and improved treatment options for this complex condition. Through these clinical trials conducted across diverse locations, we move closer to unraveling the mysteries surrounding preeclampsia while offering brighter prospects for safer pregnancies and healthier outcomes for both mothers and babies alike

Which are the best cities for preeclampsia clinical trials?

Preeclampsia clinical trials are being conducted in several cities across the United States and Canada. Among them, Pittsburgh, Pennsylvania leads with 5 active trials focusing on interventions such as Postpartum Doula Intervention Group and ARTSENS Pen. New york, New York also has 5 ongoing studies exploring treatments like 162mg ASA and Pravastatin for women with a prior history of preeclampsia. Chicago, Illinois follows closely behind with 4 active trials investigating Programmed cycle and Pravastatin among other options. Additionally, Montreal, Quebec has 3 ongoing studies including research on breastfeeding self-efficacy (BSE). Lastly, Iowa City, Iowa hosts 3 active trials studying microvascular function assessment and medications like Losartan Potassium and Salsalate Oral Tablet. These cities offer promising opportunities for individuals participating in preeclampsia clinical trials to contribute to advancing knowledge in this field of study.

Which are the top treatments for preeclampsia being explored in clinical trials?

Exciting advancements are underway in the realm of preeclampsia treatment, with various innovative approaches currently being explored in clinical trials. The top treatments on the horizon include SAIL, a groundbreaking therapy that is participating in one active trial and marking its first listing in 2022. Additionally, ARTSENS Pen, an equally promising intervention, is also undergoing investigation through one ongoing trial since its introduction in 2021. Another noteworthy contender is breastfeeding self-efficacy (BSE), which has garnered attention for its potential benefits and involvement in one current study starting from 2021. Lastly, programmed cycle stands as another intriguing avenue for preeclampsia management with participation in one active trial since it was listed back in 2020. These cutting-edge therapies hold immense promise to improve outcomes for individuals affected by this complex condition.

What are the most recent clinical trials for preeclampsia?

Recent clinical trials for preeclampsia have yielded promising results, offering potential advancements in the management and prevention of this condition. One such trial investigated the effectiveness of aspirin intervention at a dosage of 162 mg to mitigate the risks associated with preeclampsia. Another study explored the benefits of administering a lower dose (81 mg) of aspirin as a preventative measure against preeclampsia. Additionally, researchers conducted randomized trials based on USPSTF criteria to further enhance understanding and treatment strategies for this condition. With ongoing investigations into interventions and vaccinations, these groundbreaking studies bring hope for improved outcomes in individuals affected by preeclampsia.

What preeclampsia clinical trials were recently completed?

Recent advancements in the field of preeclampsia have been marked by the completion of two important clinical trials. In October 2021, Columbia University successfully concluded a trial examining the potential benefits of Furosemide as a treatment for this pregnancy-related condition. Additionally, Melanie Maykin, MD completed their own trial involving Furosemide in January 2021. These significant milestones underscore ongoing efforts to find innovative solutions and improve outcomes for women affected by preeclampsia.